Pre-made Lutikizumab benchmark antibody ( Bispecific Dual Variable Domain IG, anti-IL1A;IL1B therapeutic antibody, Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha;IL-1/IL1-BETA/IL1F2/IL1beta Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-331
Awaiting product image

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-331 Category Tags ,

For more than 100mg, click here for inquiry. >>

inquire

Product Details

Pre-Made Lutikizumab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL1A;IL1B Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha;IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Lutikizumab biosimilar, Bispecific Dual Variable Domain IG, Anti-IL1A;IL1B Antibody: Anti-IL1/IL-1A/IL1F1/IL1-ALPHA/IL-1 alpha;IL-1/IL1-BETA/IL1F2/IL1beta therapeutic antibody
INN Name

Lutikizumab
Target

IL1A,IL1B
Format

Bispecific Dual Variable Domain IG
Derivation

Bispecific antibody
Species Reactivity

Human
CH1 Isotype

IgG1
VD LC

Kappa,Kappa
Highest_Clin_Trial (Jan '20)

Phase-II
Est. Status

Discontinued
100% SI Structure

None;None
99% SI Structure

None;None
95-98% SI Structure

None;None
Year Proposed

2016
Year Recommended

2017
Companies

Abbott Laboratories,AbbVie
Conditions Approved

NA
Conditions Active

NA
Conditions Discontinued

Osteoarthritis
Development Tech

Dual Variable Domain Immunoglobulin Technology
Previous Name

NA
Gm Offical Target Name

IL1A,IL1B
Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide